The U.S. Court of Appeals for the Federal Circuit ruled that isolated DNA molecules are patentable, but struck down Myriad Genetics' method claim for comparing DNA sequences.

The SEC filed suit against Immunosyn Corp., three executives and four shareholder groups for fraudulently misleading investors regarding the progress of a drug. Some of the executives were also charged with insider trading and securities fraud.

The FDA is expanding its partnership with overseas regulatory agencies to help it meet the growing burden of inspecting foreign drug manufacturing facilities. It is extending a pilot program started in Australia and Europe.